Navigation Links
Discovery of a gene associated with a leukemia mostly affecting children
Date:1/18/2011

This release is available in French.

Montreal, January 18, 2011 Cyndia Charfi, a Ph. D student in biology at Universit du Qubec Montral (UQAM), supported by her thesis supervisors, Professor ric Rassart, and Adjunct Professor Elsy Edouard, UQAM, Department of Biological Sciences and BIOMED Research Centre, made a major breakthrough in research on B-cell acute lymphocytic leukemia, a disease that occurs most commonly in children. She has successfully identified a gene that may facilitate the diagnosis of this cancer, which is characterized by an abnormal proliferation of B-cells, antibody-producing cells that defend the body against infection. Her findings were recently published in the prestigious scientific journal Blood.

The research

Cyndi Charfi first compared the transcriptome (the set of active genes in a cell) of leukemic and healthy mice. From this analysis, she was able to isolate groups of genes with abnormal activity in the leukemic mice. This led to the discovery that excessive synthesis of the Fmn2 gene and protein is associated with B-cell lymphocytic leukemia.

Although mice cells are genetically similar to human cells, they clearly are not identical. So the young researcher continued her work, this time using human cells. Her results were the same: abormal activity of Fmn2 gene was observed in human patients with B-cell lymphocytic leukemia and particularly in children.

Better diagnosis for better treatment

Leukemia refers to all cancers that attack the bone marrow cells. The bone marrow produces blood cells, hence the term "blood cancer". As there are several types of blood cells (including B-cells), there are also several types of leukemia, and the treatment differs for each type. The faster and more accurate the diagnosis of the type of leukemia, the better the treatment.

What is the significance of this discovery? According to Professor Rassart, "although it is basic research, Cyndia Charfi's findings represent a major advance and a step closer to improved diagnosis and, hopefully, treatment of this cancer, whose victims, we should recall, are mainly children."


'/>"/>

Contact: Claire Bouchard
bouchard.claire@uqam.ca
514-987-3111
Universit du Qubec Montral
Source:Eurekalert

Related medicine news :

1. Long-shot discovery may lead to advances in treating anxiety, memory disorders
2. Researchers make critical leukemia stem cell discovery
3. New discovery prevents symptoms of rare genetic disorder
4. Discovery halts breast cancer stem cells
5. New path for colon cancer drug discovery
6. Discovery blocks cancer drugs toxic side effect
7. Discovery shows promise against severe side effects
8. Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative
9. Cell survival protein discovery rewrites immune system story
10. Gene discovery could yield treatments for nearsightedness
11. A discovery by Dr. Andre Veillettes team could impact the treatment of autoimmune diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will ... set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is ... of Medicine. He also serves as Medical Director for the Bureau of Emergency Medical ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing ... advance their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered ... few as 16 months and for as little as $14,528. These changes will enable ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
Breaking Medicine Technology: